# Panhematin for Prevention of Acute Attacks of Porphyria

> **NCT02922413** · PHASE2 · TERMINATED · sponsor: **The University of Texas Medical Branch, Galveston** · enrollment: 13 (actual)

## Conditions studied

- Acute Intermittent Porphyria
- Hereditary Coproporphyria
- Variegate Porphyria

## Interventions

- **BIOLOGICAL:** Hemin for injection
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02922413
- **Lead sponsor:** The University of Texas Medical Branch, Galveston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10-30
- **Primary completion:** 2023-12-27
- **Final completion:** 2023-12-27
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02922413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02922413, "Panhematin for Prevention of Acute Attacks of Porphyria". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02922413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*